Merck Serono's Erbitux(R) Cited As 'One Of The Most Significant Advances In The Last 25 Years' In The Treatment Of Head And Neck Cancer

Merck Serono, a division of Merck KGaA of Germany, has won a Frost & Sullivan Customer Value Enhancement (CVE) Award for its epidermal growth factor receptor (EGFR) targeted therapy Erbitux®, used in the treatment of head and neck (H&N) cancer.